Literature DB >> 18195334

Daily assessment of pain in adults with sickle cell disease.

Wally R Smith1, Lynne T Penberthy, Viktor E Bovbjerg, Donna K McClish, John D Roberts, Bassam Dahman, Imoigele P Aisiku, James L Levenson, Susan D Roseff.   

Abstract

BACKGROUND: Researchers of sickle cell disease have traditionally used health care utilization as a proxy for pain and underlying vaso-occlusion. However, utilization may not completely reflect the amount of self-reported pain or acute, painful episodes (crises).
OBJECTIVE: To examine the prevalence of self-reported pain and the relationship among pain, crises, and utilization in adults with sickle cell disease.
DESIGN: Prospective cohort study.
SETTING: Academic and community practices in Virginia. PATIENTS: 232 patients age 16 years or older with sickle cell disease. MEASUREMENTS: Patients completed a daily diary for up to 6 months, recording their maximum pain (on a scale of 0 to 9); whether they were in a crisis (crisis day); and whether they used hospital, emergency, or unscheduled ambulatory care for pain on the previous day (utilization day). Summary measures included both simple proportions and adjusted probabilities (for repeated measures within patients) of pain days, crisis days, and utilization days, as well as mean pain intensity.
RESULTS: Pain (with or without crisis or utilization of care) was reported on 54.5% of 31 017 analyzed patient-days (adjusted probability, 56%). Crises without utilization were reported on 12.7% of days and utilization on only 3.5% (unadjusted). In total, 29.3% of patients reported pain in greater than 95% of diary days, whereas only 14.2% reported pain in 5% or fewer diary days (adjusted). The frequency of home opiate use varied and independently predicted pain, crises, and utilization. Mean pain intensity on crisis days, noncrisis pain days, and total pain days increased as the percentage of pain days increased (P < 0.001). Intensity was significantly higher on utilization days (P < 0.001). However, utilization was not an independent predictor of crisis, after controlling for pain intensity. LIMITATIONS: The study was done in a single state. Patients did not always send in their diaries.
CONCLUSION: Pain in adults with sickle cell disease is the rule rather than the exception and is far more prevalent and severe than previous large-scale studies have portrayed. It is mostly managed at home; therefore, its prevalence is probably underestimated by health care providers, resulting in misclassification, distorted communication, and undertreatment.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18195334     DOI: 10.7326/0003-4819-148-2-200801150-00004

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  204 in total

1.  Increased clearance of morphine in sickle cell disease: implications for pain management.

Authors:  Deepika S Darbari; Michael Neely; John van den Anker; Sohail Rana
Journal:  J Pain       Date:  2011-02-01       Impact factor: 5.820

2.  American Society of Hematology 2020 guidelines for sickle cell disease: management of acute and chronic pain.

Authors:  Amanda M Brandow; C Patrick Carroll; Susan Creary; Ronisha Edwards-Elliott; Jeffrey Glassberg; Robert W Hurley; Abdullah Kutlar; Mohamed Seisa; Jennifer Stinson; John J Strouse; Fouza Yusuf; William Zempsky; Eddy Lang
Journal:  Blood Adv       Date:  2020-06-23

3.  CE: Understanding the Complications of Sickle Cell Disease.

Authors:  Paula Tanabe; Regena Spratling; Dana Smith; Peyton Grissom; Mary Hulihan
Journal:  Am J Nurs       Date:  2019-06       Impact factor: 2.220

4.  Dexmedetomidine ameliorates nocifensive behavior in humanized sickle cell mice.

Authors:  Gabriela Calhoun; Li Wang; Luis E F Almeida; Nicholas Kenyon; Nina Afsar; Mehdi Nouraie; Julia C Finkel; Zenaide M N Quezado
Journal:  Eur J Pharmacol       Date:  2015-02-25       Impact factor: 4.432

5.  A retrospective review of acupuncture use for the treatment of pain in sickle cell disease patients: descriptive analysis from a single institution.

Authors:  Kit Lu; Mok-Chung Jennifer Cheng; Xiaoying Ge; Ann Berger; Dihua Xu; Gregory J Kato; Caterina P Minniti
Journal:  Clin J Pain       Date:  2014-09       Impact factor: 3.442

6.  Changes in Pain and Psychosocial Functioning and Transition to Chronic Pain in Pediatric Sickle Cell Disease: A Cohort Follow-up Study.

Authors:  Soumitri Sil; Lindsey L Cohen; Nitya Bakshi; Amanda Watt; Morgan Hathaway; Farida Abudulai; Carlton Dampier
Journal:  Clin J Pain       Date:  2020-06       Impact factor: 3.442

Review 7.  Key Components of Pain Management for Children and Adults with Sickle Cell Disease.

Authors:  Amanda M Brandow; Michael R DeBaun
Journal:  Hematol Oncol Clin North Am       Date:  2018-06       Impact factor: 3.722

8.  Glucocorticoid receptor single nucleotide polymorphisms are associated with acute crisis pain in sickle cell disease.

Authors:  Ellie H Jhun; Nilanjana Sadhu; Yingwei Yao; Ying He; Robert E Molokie; Diana J Wilkie; Zaijie Jim Wang
Journal:  Pharmacogenomics       Date:  2018-08-06       Impact factor: 2.533

9.  Mechanism-driven phase I translational study of trifluoperazine in adults with sickle cell disease.

Authors:  Robert E Molokie; Diana J Wilkie; Harriett Wittert; Marie L Suarez; Yingwei Yao; Zhongsheng Zhao; Ying He; Zaijie J Wang
Journal:  Eur J Pharmacol       Date:  2013-11-07       Impact factor: 4.432

10.  DNA polymorphisms at the BCL11A, HBS1L-MYB, and beta-globin loci associate with fetal hemoglobin levels and pain crises in sickle cell disease.

Authors:  Guillaume Lettre; Vijay G Sankaran; Marcos André C Bezerra; Aderson S Araújo; Manuela Uda; Serena Sanna; Antonio Cao; David Schlessinger; Fernando F Costa; Joel N Hirschhorn; Stuart H Orkin
Journal:  Proc Natl Acad Sci U S A       Date:  2008-07-30       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.